<span item_type="fundamental" item_id="32de6220c5ed53d96783356d846b0f3e" counter_id="ST/US/CDTTW" env="prod"></span><span item_type="announcement" item_id="582444662939589889" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 0.</p><p>EPS: As of FY2025 Q3, the actual value is USD -13.16.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -6.992 M.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Research &amp; Development Expenses</strong>: $1.5 million for the three months ended September 30, 2025, compared to $3.1 million for the same period in 2024, representing a 50% decrease. For the nine months ended September 30, 2025, expenses were $4.3 million, up from $3.2 million in 2024, a 33% increase.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1896212/000149315225022373/form10-q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Loss</strong>: $7.1 million for the three months ended September 30, 2025, compared to $6.5 million for the same period in 2024. For the nine months ended September 30, 2025, the net loss was $17.9 million, compared to $15.4 million in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1896212/000149315225022373/form10-q.htm"></span></li><li><strong>General and Administrative Expenses</strong>: Increased by 102% to $5.5 million for the three months ended September 30, 2025, from $2.7 million in 2024. For the nine months ended September 30, 2025, expenses were $11.3 million, up from $8.7 million in 2024, a 30% increase.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1896212/000149315225022373/form10-q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Operating Cash Flow</strong>: Net cash used in operating activities was $10.9 million for the nine months ended September 30, 2025, compared to $5.9 million in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1896212/000149315225022373/form10-q.htm"></span></li><li><strong>Free Cash Flow</strong>: Not explicitly stated, but the net increase in cash and cash equivalents was $3.3 million for the nine months ended September 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1896212/000149315225022373/form10-q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Digital Assets</strong>: The company held Bitcoin valued at approximately $1.0 million as of September 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1896212/000149315225022373/form10-q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: CDT Equity Inc. plans to continue leveraging AI and solid-form chemistry to enhance drug properties and extend patent life. The company aims to exit through third-party license deals following successful pre-clinical trials.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1896212/000149315225022373/form10-q.htm"></span></li><li><strong>Non-Core Business</strong>: The company is exploring a shift towards a digital asset treasury management strategy as an alternative path for fundraising.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1896212/000149315225022373/form10-q.htm"></span></li><li><strong>Priority</strong>: The company emphasizes strategic partnerships and AI-driven insights to optimize drug development and asset management, aiming for efficiency and cost reduction.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1896212/000149315225022373/form10-q.htm"></span></li></ul>

CDT EQUITY INC C/WTS 22/09/2028(TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 0